Table 3.

Multivariable analysis of patients who underwent allogeneic transplants for AML, ALL, CML, MDS and had Invasive fungal infection within 12 months prior to transplant vs. those who had no documented invasive fungal infection within 12 months prior to transplant, reported to the CIBMTR, from 2001 to 2009

Variable	2 yr OS RR (95% CI)	p	2 yr PFS RR (95% CI)	p	2 yr NRM RR (95% CI)	p	2 yr Relapse RR (95% CI)	p
Main Effect		<0.0001		<0.0001		0.002		NS
Control	1.00		1.00		1.00		1.00
Pre-HSCT IFI	1.33 (1.19 – 1.48)		1.24 (1.11 – 1.38)		1.27 (1.09 – 1.49)		1.04 (0.91 – 1.18)
Age, years		<0.0001		<0.0001		<0.0001		NS
≤ 10	1.00		1.00		1.00
11 – 20	1.21 (1.06 – 1.39)	0.0051	1.21 (1.06 – 1.37)	0.0039	1.75 (1.41 – 2.17)	<0.0001
21 – 30	1.28 (1.12 – 1.48)	0.0004	1.33 (1.17 – 1.51)	<0.0001	1.79 (1.43 – 2.24)	<0.0001
31 – 40	1.47 (1.28 – 1.69)	<0.0001	1.44 (1.27 – 1.65)	<0.0001	2.32 (1.86 – 2.89)	<0.0001
41 – 50	1.58 (1.38 – 1.81)	<0.0001	1.56 (1.37 – 1.77)	<0.0001	2.48 (1.99 – 3.08)	<0.0001
> 50	1.81 (1.59 – 2.06)	<0.0001	1.70 (1.50 – 1.93)	<0.0001	2.86 (2.30 – 3.55)	<0.0001
Ex vivo TCD		0.0008		<0.0001		NS		<0.0001
None	1.00		1.00				1.00
ATG	1.09 (1.02 – 1.18)	0.0128	1.37 (1.06 – 1.22)	0.0002			1.12 (1.03 – 1.22)	0.0109
Alemtuzumab	1.28 (1.11 – 1.48)	0.0006	1.58 (1.37 – 1.81)	<0.0001			1.71 (1.46 – 2.01)	<0.0001
D/R CMV status		<0.0001		0.0003		0.0136		0.0295
Neg/Neg	1.00		1.00		1.00		1.00
Pos/Pos	1.19 (1.10 – 1.29)	<0.0001	1.16 (1.07 – 1.25)	0.0002	1.16 (1.02 – 1.31)	0.0206	1.10 (1.00 – 1.21)	0.0540
Pos/Neg	1.12 (1.00 – 1.26)	0.0459	1.07 (0.96 – 1.20)	0.1948	1.17 (0.99 – 1.38)	0.0614	1.00 (0.87 – 1.15)	0.9923
Neg/Pos	1.21 (1.10 – 1.32)	<0.0001	1.19 (1.10 – 1.29)	<0.0001	1.17 (1.03 – 1.33)	0.0127	1.14 (1.03 – 1.26)	0.0113
Missing	1.20 (1.12 – 1.41)	0.0319	1.15 (0.98 – 1.35)	0.0873	1.44 (1.15 – 1.80)	0.0015	0.93 (0.75 – 1.14)	0.4886
Disease		<0.0001		<0.0001		<0.0001		<0.0001
AML	1.00		1.00		1.00		1.00
ALL	1.10 (1.02 – 1.19)	0.0119	1.17 (1.08 – 1.26)	<0.0001	1.36 (1.21 – 1.53)	<0.0001	0.95 (0.87 – 1.04)	0.2955
CML	0.84 (0.78 – 0.93)	0.0004	1.02 (0.93 – 1.11)	0.6934	1.32 (1.15 – 1.50)	<0.0001	0.82 (0.73 – 0.92)	0.0006
MDS	0.64 (0.56 – 0.73)	<0.0001	0.67 (0.59 – 0.75)	<0.0001	1.02 (0.85 – 1.23)	0.8239	0.60 (0.52 – 0.69)	<0.0001
Disease Stage		<0.0001		<0.0001		0.0286		<0.0001
Early	1.00		1.00		1.00		1.00
Intermediate	1.27 (1.18 – 1.36)	<0.0001	1.24 (1.15 – 1.33)	<0.0001	1.15 (1.03 – 1.28)	0.0094	1.24 (1.14 – 1.36)	<0.0001
Advanced	2.24 (2.01 – 2.42)	<0.0001	2.13 (1.98 – 2.30)	<0.0001	1.10 (0.97 – 12.3)	0.1289	2.33 (2.13 – 2.54)	<0.0001
Donor		<0.0001		<0.0001		<0.0001		<0.0001
HLA ID-sib	1.00		1.00		1.00		1.00
Other related	1.64 (1.38 – 1.93)	<0.0001	1.47 (1.25 – 1.72)	<0.0001	1.82 (1.47 – 2.27)	<0.0001	0.93 (0.77 – 1.13)	0.4968
Cord	1.32 (1.18 – 1.47)	<0.0001	1.21 (1.09 – 1.35)	0.0004	2.01 (1.70 – 2.38)	<0.0001	0.77 (0.67 – 0.89)	0.0004
WM unrelated	0.88 (0.81 – 0.95)	0.0015	0.87 (0.80 – 0.93)	0.0002	1.11 (0.98 – 1.25)	0.0870	0.76 (0.69 – 0.84)	<0.0001
Other unrelated	1.14 (1.04 – 1.25)	0.0038	1.04 (0.95 – 1.13)	0.3625	1.78 (1.56 – 2.01)	<0.0001	0.66 (0.59 – 0.74)	<0.0001
Karnosky PS		<0.0001		<0.0001		<0.0001		<0.0001
≥ 90%	1.00		1.00		1.00		1.00
< 90%	1.38 (1.29 – 1.47)	<0.0001	1.32 (1.24 – 1.41)	<0.0001	1.26 (1.14 – 1.39)	<0.0001	1.21 (1.12 – 1.31)	<0.0001
Missing	1.27 (1.04 – 1.40)	0.0114	1.14 (1.00 – 1.31)	0.0588	1.15 (0.94 – 1.42)	0.1807	1.12 (0.95 – 1.33)	0.1746
Conditioning		NS		<0.0001		<0.0001		<0.0001
Myeloablative			1.00		1.00		1.00
RIC/NMA			1.15 (1.07 – 1.23)		0.79 (0.71 – 0.88)		1.36 (1.25 – 1.47)